The Board of Directors of
The Extraordinary General Meeting of Sobi on
The Board of Directors has today resolved to issue 602,482 series C shares. The right to subscribe for the new series C shares shall, with deviation from the shareholders' preferential right to subscribe for shares, be granted
Upon repurchase of all 602,482 series C shares, the intention is to convert the repurchased series C shares into common shares pursuant to the conversion provision in Sobi's articles of association to secure future delivery of common shares to the participants in the outstanding incentive programmes. The intent is to repurchase and convert the shares as soon as possible after the share issue.
Sobi currently holds 14,294,637 own common shares and no own series C shares. Following the repurchase and conversion of the series C shares to common shares, Sobi will hold 14,897,119 own common shares.
Sobi
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-issues-series-c-shares-to-fulfil-its-obligations-under-outstanding-incentive-programmes,c3866279
https://mb.cision.com/Main/14266/3866279/2397828.pdf
(c) 2023 Cision. All rights reserved., source